Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Vera Therapeutics Inc
VERA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$27.88
-0.69
-2.42%
Ult. Agg.: Oct 16, 7:14 PM
$27.50
-1.07
-3.75%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Vera Therapeutics Financials
Vera Therapeutics (VERA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from
Benzinga Newsdesk
PRO
Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.34) by 26.12 percent. This is a 108.64 percent decrease over losses of $(0.81) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.31) by 6.19 percent. This is a 93.06 percent decrease over losses of $(0.72) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q3 EPS $(1.26) Misses $(1.16) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.16) by 8.71 percent. This is a 48.24 percent decrease over losses of $(0.85) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q2 2025 EPS $(1.20) Misses $(0.83) Estimate, Vera Reported $556.8M In Cash, Cash Equivalents, And Marketable Securities
Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept anticipated in 2026 and beyond
Benzinga Newsdesk
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results
Avi Kapoor
